Tower Research Capital (TRC)’s Unicycive Therapeutics UNCY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$14.5K Buy
3,084
+1,296
+72% +$6.72K ﹤0.01% 3993
2026
Q2
$8.39K Buy
+1,788
New +$13.2K ﹤0.01% 4077
2026
Q1
– Sell
-1,920
Closed -$11.1K – 5581
2025
Q4
$11.1K Buy
+1,920
New +$10.2K ﹤0.01% 3656
2025
Q1
– Sell
-1,089
Closed -$8.64K – 5808
2024
Q4
$8.64K Sell
1,089
-1,189
-52% -$6.58K ﹤0.01% 3979
2024
Q3
$9.3K Buy
2,278
+429
+23% +$1.72K ﹤0.01% 3881
2024
Q2
$9.26K Buy
1,849
+1,081
+141% +$10.6K ﹤0.01% 4272
2024
Q1
$10.6K Buy
768
+92
+14% +$1.12K ﹤0.01% 3677
2023
Q4
$5.87K Buy
676
+369
+120% +$2.41K ﹤0.01% 4796
2023
Q3
$2.64K Buy
307
+100
+48% +$937 ﹤0.01% 5126
2023
Q2
$2.65K Sell
207
-135
-39% -$2.11K ﹤0.01% 5172
2023
Q1
$7K Sell
342
-158
-32% -$1.57K ﹤0.01% 4778
2022
Q4
$3K Sell
500
-18
-3% -$122 ﹤0.01% 5244
2022
Q3
$3K Buy
518
+1
+0.2% +$7 ﹤0.01% 5433
2022
Q2
$4K Buy
517
+133
+35% +$1.27K ﹤0.01% 5260
2022
Q1
$5K Buy
+384
New +$5.62K ﹤0.01% 5108

Other funds holding UNCY

Tower Research Capital (TRC)'s UNCY Position: Q3 2026 in Review

Tower Research Capital (TRC) increased its Unicycive Therapeutics (UNCY) stake by 72% in Q3 2026, buying an estimated $6.72K and bringing the position to 3,084 shares worth $14.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3993.

Tower Research Capital (TRC) first reported a position in UNCY in Q1 2022 and has held it in 15 quarters since. 95 funds tracked by Wall St. Rank hold UNCY as of Q3 2026.

  • Tower Research Capital (TRC) held 3,084 shares of Unicycive Therapeutics worth $14.5K as of Q3 2026.
  • Tower Research Capital (TRC) bought 1,296 Unicycive Therapeutics shares in Q3 2026, an estimated $6.72K.
  • Unicycive Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #3993 holding.
  • Tower Research Capital (TRC) first reported a position in Unicycive Therapeutics in Q1 2022 and has held it in 15 quarters since.
  • 95 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q3 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.